secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALISADE BIO, INC. (PALI)
CIK:        0001357459
Form:       8-K
Filed at:   2022-10-14T23:59:59+00:00
Accession:  0001493152-22-028453
Event type: leadership
Sentiment:  negative
Materiality: 0.60
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palisade Bio CEO Thomas Hallam resigns; CFO JD Finley appointed interim CEO
---------------------------------------------------------------------------

- CEO Thomas Hallam resigned effective Oct 11, 2022; separation agreement includes $530,000 paid over 12 months, COBRA, accelerated vesting.
- JD Finley, current CFO, appointed interim CEO effective Oct 10; will continue as CFO.
- Company will not present at American College of Surgeons Clinical Congress 2022 to focus on internal reorganization.
- Dr. Hallam's resignation not due to any disagreement on operations, policies, or practices.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357459/000149315222028453/0001493152-22-028453-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357459/000149315222028453/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-028453

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer